South Korea court ends long legal battle for Samsung chief
The ruling clears Lee of accounting fraud and stock manipulation charges tied to the US$8 billion merger between Samsung C&T and Cheil Industries. Prosecutors argued that the deal was engineered to consolidate Lee's control over the conglomerate following his father's incapacitation.
The Supreme Court's decision affirms two earlier rulings, including one from an appeals court that found no wrongdoing in the merger.
Lee's legal team welcomed the outcome, saying in a statement they were "sincerely grateful" to the court and that the ruling confirmed the merger was legal.
The case had cast a long shadow over Lee's leadership at Samsung for nearly a decade, beginning shortly after the 2014 heart attack that left his father, Samsung patriarch Lee Kun-hee, in a coma. The merger laid the foundation for Lee's succession at the helm of the tech empire.
While the verdict had been widely anticipated, it arrives at a pivotal time. Samsung is in a race to close the gap in AI chip development, facing fierce global competition in a fast-evolving semiconductor industry.
The Supreme Court's decision removes a lingering legal distraction, allowing Lee to focus entirely on steering Samsung through one of its most strategically significant periods.
Samsung Electronics shares were modestly higher after the ruling, rising 1.7 percent.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
16 minutes ago
- Globe and Mail
Avant Technologies' Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference
LAS VEGAS , July 22, 2025 /CNW/ -- Avant Technologies Inc. (OTCQB: AVAI) ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas , Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia . The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America . Ainnova's CEO, Vinicio Vargas , who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego , Hugo Ocampo , and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems. In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading prepaid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy. If the program is successful, Avant and Ainnova hope to implement a similar program in the United States , Canada , and Europe through AAC. AAC has the worldwide licensing rights for Ainnova's technology portfolio, which includes Ainnova's Vision AI platform. About Ainnova Tech, Inc. Ainnova is a Nevada -based healthtech startup with headquarters in San Jose, Costa Rica , and Houston, Texas . Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions. About Avant Technologies Inc. Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology. More information about Avant can be found at You can also follow us on social media at: Forward-Looking Statements Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website ( In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Globe and Mail
16 minutes ago
- Globe and Mail
Accelo Expands Leadership Position in Professional Services Automation with Acquisition of Forecast, an AI-Enabled SaaS Platform Headquartered in the UK
DENVER , July 22, 2025 /CNW/ -- Accelo, a cloud-based platform for Professional Services Automation (PSA), announced today its acquisition of UK-based PSA firm, Forecast, a global provider of AI-powered project and resource management software. This strategic acquisition further strengthens Accelo's leadership in the PSA market and expands its capabilities in predictive planning, resource optimization, and intelligent automation. The merged company's global headquarters is in Denver, CO with offices in Wollongong, Australia and the UK. The combined entity will offer an even more powerful and comprehensive PSA solution, enabling professional services businesses to: Improve Project Profitability: Gain real-time insights into project costs, revenue, and margins, allowing for proactive adjustments and optimized financial outcomes. Enhance Resource Optimization: Utilize AI-powered forecasting and scheduling to allocate the right resources to the right projects at the right time, maximizing utilization and minimizing bench time alongside accurate and seamless timekeeping. Streamline Operations: Automate workflows from sales and project delivery to billing and reporting, reducing administrative overhead and accelerating the quote-to-cash cycle. Drive Data-Driven Decisions: Access unified data and advanced analytics to make informed strategic decisions and identify areas for growth and improvement. Expand Global Reach: Strengthen Accelo's presence in the UK and European markets, providing enhanced support and localized solutions to a broader client base. Karen Sawyer , CEO of Accelo, states, "We're extremely enthusiastic about Forecast's people, products, and most importantly, their customers; this compelling merger of strengths combines Forecast's AI-powered insights with Accelo's unified Professional Services Automation platform." Sawyer then says, "We are building a smarter, more agile solution that provides global enterprise clients the critical insights and comprehensive controls required for high-quality, profitable project delivery." Dennis Kayser , Founder and CEO of Forecast, added, "From inception, we envisioned building a market-leading, native AI-enabled PSA system to support the world's best run consultancies regardless of size and unique business model requirements." Kayser further stated, "With significant growth capital from Bow River Capital, and this combination with Accelo, we have capabilities to significantly enhance product roadmap innovations and will double-down on strategic client success investments and services." Maitlan Cramer, Lead Accelo board member with Bow River Capital's Software Growth Equity Team, said, "We're thrilled to announce the acquisition of Forecast; this strategic combination and incremental growth capital creates a much larger cohort of high-quality, enterprise clients across Europe , North America , and Asia-Pac. The combined entity will significantly enhance acceleration of our product roadmap and scale." Charles Chen , an Accelo Board member and Partner at Level Equity, stated, "We have strong conviction in the Professional Services Automation industry, and are thrilled with the value creation progress since the recapitalization with our partners at Bow River Capital." The Forecast team will join Accelo to accelerate innovation across both platforms, with a shared vision to eliminate operational blind spots and empower teams to do their best work. Customers of both platforms can expect continued support and improvements, with future product enhancements driven by collaborative innovation and customer feedback. This acquisition comes at a time when demand for unified, insight-driven operations continues to rise among professional services organizations. As teams face increasing pressure to optimize resources, control margins, and deliver exceptional client outcomes, the combination of Accelo and Forecast offers an unmatched solution that connects work, people, and financials in real time. About Accelo Accelo is a cloud-based Professional Services Automation (PSA) platform that helps professional services-based businesses streamline operations, improve efficiency, and scale profitably. Designed for industries such as consulting, accounting, engineering, architecture, IT services, and marketing agencies, Accelo replaces fragmented tools with a single, integrated system for managing clients, projects, resources, and finances. By unifying the quote-to-cash lifecycle, Accelo enables businesses to automate workflows, track projects, optimize resource allocation, and gain real-time visibility into operations. With built-in CRM, project tracking, scheduling, invoicing, and analytics, Accelo empowers professional services firms to improve productivity, enhance team collaboration, and drive sustainable growth. About Forecast The Forecast AI-native platform is a system of intelligence that represents the most advanced technology ever applied to managing finances, resources and projects. Forecast is the ultimate upgrade for any project team and organization. Our platform automates busywork, surfaces best practices, predicts outcomes, guides projects to success, and most importantly empowers every team member to do their best work. Technology doing what it does best, so humans can do what they do best. For more information about the acquisition and what it means for Accelo and Forecast customers, visit
National Post
an hour ago
- National Post
Real Chemistry Deepens Media and Technology Edge With Acquisition of Greater Than One
Article content Acquisition brings proprietary media planning and analytics tools into Real Chemistry's platform – enhancing strategy, performance and measurable impact for pharma and biotech clients. Article content NEW YORK — Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, today announced it has acquired Greater Than One, an award-winning agency specializing in healthcare-first media, technology and omnichannel strategy. The acquisition brings expanded precision, stronger performance analytics and greater strategic clarity to Real Chemistry clients along every step of the commercialization journey. Article content 'Greater Than One brings deep media expertise, powerful proprietary tools and a culture that matches ours—focused, fast-moving and built to deliver results,' said Shankar Narayanan, CEO of Real Chemistry. 'Greater Than One brings deep media expertise, powerful proprietary tools and a culture that matches ours—focused, fast-moving and built to deliver results,' said Shankar Narayanan, CEO of Real Chemistry. 'Together, we'll help clients make smarter decisions and create more meaningful engagement with the audiences who matter most. We are rewriting the next chapter of what's possible for healthcare marketing and adding Greater Than One to our team gives us even more firepower to drive this revolution.' Article content Precision That Drives Performance Article content Founded nearly 25 years ago, Greater Than One has earned a reputation for helping healthcare brands get the most from their omnichannel and media investments through a combination of data, predictive modeling and proprietary planning tools. These include: Article content Greater Reach, a predictive media planning engine that helps brands model budget and channel mix based on audience and engagement goals. Greater Score, an advanced engagement scoring tool that empowers healthcare brand marketers and sales teams by providing a holistic view of healthcare professional interactions across all addressable media and CRM channels that helps marketers prioritize outreach and improve performance. Greater Omni, Greater Than One's centralized omnichannel platform strategy and implementation capability, gives teams real-time visibility across campaigns—so clients know what's working, where to spend, and how to pivot. Their Omnichannel Maturity Model breaks the process down into clear, actionable stages – no jargon, just a roadmap to smarter engagement, better measurement and stronger returns. Article content These capabilities will be integrated into Real Chemistry's platform – giving clients access to unified planning, measurement and activation strategies grounded in data-driven behavioral science. Article content At the same time, Greater Than One clients will benefit from Real Chemistry's offerings in AI-driven strategy, creative, influencer engagement, medical communications, integrated communications and market access – unlocking a more complete and connected experience for healthcare marketers. Article content 'This move multiplies our capability,' said Kevin Johnson, Group President and Managing Partner at Real Chemistry. 'In a healthcare environment that demands more agility and precision than ever, Greater Than One brings the technology, talent, and focus to help us deliver faster decisions, smarter planning, and measurable impact where it matters most.' Article content Aligned Cultures. Shared Ambition. Integrated Growth. Article content Greater Than One's employees will join Real Chemistry and continue operating under the brand Greater Than One, part of Real Chemistry. The agency will maintain its New York headquarters and remote-first structure. Article content 'Finding a match like Real Chemistry, where our employees and clients will benefit, is exactly what we wanted for Greater Than One,' said Elizabeth Izard Apelles, President and CEO, Greater Than One. 'Our shared belief that building innovative, client-first partnerships leads to impact and results is a powerful force behind this acquisition.' Article content Terms of the transaction are not disclosed. Article content The acquisition builds on a year of strong momentum for Real Chemistry, which was ranked the No. 2 Healthcare Network at Cannes Lions Health 2025, named PRWeek's no. 1 PR Agency, and placed no. 3 on MM+M's Agency 100. The firm was also honored as Outstanding Healthcare Agency of the Year at the 2025 PRWeek U.S. Awards – underscoring its consistent leadership in strategy, innovation and measurable client impact in healthcare. Article content About Greater Than One Article content Greater Than One, part of Real Chemistry, is an advanced media and technology agency serving the healthcare industry. The agency delivers precision media, proprietary technology solutions, and strategic expertise to help clients navigate complexity and drive measurable growth. Greater Than One's unique technology products empowers marketers to understand customer journeys, build evidence-based strategies, forecast marketing budgets, and take actionable steps to drive prescriptions. Article content About Real Chemistry Article content Article content Article content Article content Article content Article content
